Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Although the clinical outcomes of patients with B-cell malignancies such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia have improved during the past decade, many continue to develop relapsed or refractory disease, representing a significant cause of morbidity and mortality. CAR T-cell therapy has been shown to produce significant antitumor responses in these patients, for whom treatment options are limited. However, CAR T-cell therapy is associated with serious adverse events such as cytokine release syndrome (CRS), neurotoxicity, anaphylaxis, B-cell aplasia, and tumor lysis syndrome. In addition, the development of resistance to CAR T-cell therapy represents a significant clinical challenge.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with B-cell malignancies.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Describe the T-cell manufacturing workflow
2. Differentiate emerging efficacy and safety data on CAR T-cell therapy for relapsed/refractory B-cell malignancies
3. Apply strategies to manage adverse events associated with CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Expiration

Feb 20, 2020

Discipline(s)

Nurse Practitioner , Nursing CNE

Format

Monograph, Online

Credits / Hours

1.0

Accreditation

ANCC

Presenters / Authors / Faculty

Stephanie Jackson, MSN, RN, AOCNS®, BMTCN® (Chairperson)
Oncology Clinical Nurse Specialist
Ronald Reagan UCLA Medical Center

Leslie Smith, RN, APRN-CNS, AOCNS®
Oncology and Transplant Clinical Nurse Specialist
National Institutes of Health Clinical Center

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Gilead.

Keywords / Search Terms

i3 Health i3 Health, CAR T, CAR T-cell, oncology, hematology, hematology/oncology, supportive care, B-cell malignancies, acute lymphoblastic leukemia, non-Hodgkin lymphoma, cytokine release syndrome, neurotoxicity, CE, free CE Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.